Neurobiological Technologies, Inc. (NASDAQ: NTII) Q2/07 Review Issued by Scimitar Equity Research, Inc.
February 13 2007 - 9:00AM
PR Newswire (US)
BOSTON, Feb. 13 /PRNewswire/ -- Scimitar Equity Research, Inc.
(Scimitar) issues a review of Neurobiological Technologies, Inc.
(NASDAQ:NTII), entitled, "Royalties Pour In, Momentum Rebuilds,
Losses Decrease and Encouraging Viprinex(TM) Clinical Trials
Advance Supported by the Role of Fibrinogen in Influencing Stroke
Outcome." This review is available at our website:
http://www.scimitarequity.com/. Neurobiological Technologies, Inc.
(NTII) is a biotechnology company engaged in the business of
acquiring and developing central nervous system related drug
candidates. NTII is focused on therapies for neurological
conditions that occur in connection with ischemic stroke, brain
cancer, Alzheimer's disease and dementia. NTII's strategy is to
in-license and develop later-stage drug candidates that target
major medical needs and that can be rapidly commercialized. NTII's
experienced management team oversees the human clinical trials
necessary to establish preliminary evidence of efficacy. For
further information, please visit NTII's website at
http://www.ntii.com/. Scimitar Equity Research, Inc. provides
sponsored equity research of the health sciences industry for the
institutional and investment communities. We certify that all the
views expressed in this review, accurately reflect our personal
views about NTII (NASDAQ) and its or their securities. No part of
our compensation was, is, or will be, directly or indirectly,
related to the specific recommendations or views contained in this
review and we will not have any investment banking relationships or
personal investment in any sponsored company. Investors are advised
that this analysis and review is issued solely for informational
purposes and is not to be construed as an offer to sell or the
solicitation of an offer to buy. Scimitar was paid for preparing
this review. This analysis and review does not have regard to the
specific investment objectives, financial situation and the
information contained herein is based on sources that we believe to
be reliable but is not guaranteed by us as being accurate and does
not purport to be a complete statement or summary of the available
data. Any opinions expressed are statements of our own judgment as
of the date of publication and are subject to change without
notice. Please read all our important disclosures. CONTACT:
Scimitar Equity Research, Inc. Henry W. McCusker Director of
Research phone: (617) 559.1080 fax: (617) 559.1083 e-mail:
DATASOURCE: Scimitar Equity Research, Inc. CONTACT: Henry W.
McCusker, Director of Research, Scimitar Equity Research, Inc.,
+1-617-559-1080, or fax, +1-617-559-1083, or Web site:
http://www.scimitarequity.com/ http://www.ntii.com/
Copyright
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Sep 2023 to Sep 2024